These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18663410)

  • 1. Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer.
    Gullo G; Bettio D; Torri V; Masci G; Salvini P; Santoro A
    Invest New Drugs; 2009 Apr; 27(2):179-83. PubMed ID: 18663410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.
    Han HS; Kim JS; Park JH; Jeon YK; Lee KW; Oh DY; Kim JH; Park SY; Im SA; Kim TY; Park IA; Bang YJ
    J Korean Med Sci; 2009 Oct; 24(5):910-7. PubMed ID: 19794992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.
    Lee HJ; Seo AN; Kim EJ; Jang MH; Suh KJ; Ryu HS; Kim YJ; Kim JH; Im SA; Gong G; Jung KH; Park IA; Park SY
    Am J Clin Pathol; 2014 Dec; 142(6):755-66. PubMed ID: 25389328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Level of HER2/neu amplification in primary tumours and metastases in HER2-positive breast cancer and survival after trastuzumab therapy.
    Gullo G; Bettio D; Zuradelli M; Masci G; Giordano L; Bareggi C; Tomirotti M; Salvini P; Runza L; La Verde N; Santoro A
    Breast; 2013 Apr; 22(2):190-193. PubMed ID: 23473771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.
    Mass RD; Press MF; Anderson S; Cobleigh MA; Vogel CL; Dybdal N; Leiberman G; Slamon DJ
    Clin Breast Cancer; 2005 Aug; 6(3):240-6. PubMed ID: 16137435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
    Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.
    Stocker A; Hilbers ML; Gauthier C; Grogg J; Kullak-Ublick GA; Seifert B; Varga Z; Trojan A
    PLoS One; 2016; 11(7):e0159176. PubMed ID: 27463363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
    Gori S; Sidoni A; Colozza M; Ferri I; Mameli MG; Fenocchio D; Stocchi L; Foglietta J; Ludovini V; Minenza E; De Angelis V; Crinò L
    Ann Oncol; 2009 Apr; 20(4):648-54. PubMed ID: 19188134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
    Lee HJ; Kim JY; Park SY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
    Am J Clin Pathol; 2015 Oct; 144(4):570-8. PubMed ID: 26386078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
    Dybdal N; Leiberman G; Anderson S; McCune B; Bajamonde A; Cohen RL; Mass RD; Sanders C; Press MF
    Breast Cancer Res Treat; 2005 Sep; 93(1):3-11. PubMed ID: 16184453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.
    Perez EA; Roche PC; Jenkins RB; Reynolds CA; Halling KC; Ingle JN; Wold LE
    Mayo Clin Proc; 2002 Feb; 77(2):148-54. PubMed ID: 11838648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
    Dowsett M; Procter M; McCaskill-Stevens W; de Azambuja E; Dafni U; Rueschoff J; Jordan B; Dolci S; Abramovitz M; Stoss O; Viale G; Gelber RD; Piccart-Gebhart M; Leyland-Jones B
    J Clin Oncol; 2009 Jun; 27(18):2962-9. PubMed ID: 19364966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.
    Hanna WM; Rüschoff J; Bilous M; Coudry RA; Dowsett M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
    Mod Pathol; 2014 Jan; 27(1):4-18. PubMed ID: 23807776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab.
    Bates M; Sperinde J; Köstler WJ; Ali SM; Leitzel K; Fuchs EM; Paquet A; Lie Y; Sherwood T; Horvat R; Singer CF; Winslow J; Weidler JM; Huang W; Lipton A
    Ann Oncol; 2011 Sep; 22(9):2014-2020. PubMed ID: 21289364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
    Nishimura R; Okumura Y; Arima N
    Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
    Vogel CL; Cobleigh MA; Tripathy D; Gutheil JC; Harris LN; Fehrenbacher L; Slamon DJ; Murphy M; Novotny WF; Burchmore M; Shak S; Stewart SJ; Press M
    J Clin Oncol; 2002 Feb; 20(3):719-26. PubMed ID: 11821453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: a case report.
    Takahashi M; Inoue K; Goto R; Tamura M; Taguchi K; Takahashi H; Suzuki H; Katsushige K; Ogita M
    Breast Cancer; 2003; 10(2):170-4. PubMed ID: 12736573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.